INT55537

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1994
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 22
Total Number 23
Disease Relevance 8.17
Pain Relevance 8.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (Coq10a) cellular_component (Coq10a) biological_process (Coq10a)
Anatomy Link Frequency
brain 3
neurons 2
vesicles 2
DRG 2
F11 2
Coq10a (Mus musculus)
Pain Link Frequency Relevance Heat
Opioid 51 100.00 Very High Very High Very High
cerebral cortex 19 100.00 Very High Very High Very High
MU agonist 7 99.88 Very High Very High Very High
Morphine 2 99.38 Very High Very High Very High
dorsal root ganglion 12 99.28 Very High Very High Very High
adenocard 11 99.24 Very High Very High Very High
opioid receptor 27 99.12 Very High Very High Very High
fortral 7 98.08 Very High Very High Very High
narcan 16 98.00 Very High Very High Very High
tolerance 2 97.64 Very High Very High Very High
Disease Link Frequency Relevance Heat
Ataxia 95 100.00 Very High Very High Very High
Ganglion Cysts 28 99.64 Very High Very High Very High
Neuroblastoma 13 98.82 Very High Very High Very High
Neurodegenerative Disease 180 96.36 Very High Very High Very High
Frailty 27 96.22 Very High Very High Very High
Weight Loss 15 95.86 Very High Very High Very High
Disease 287 94.08 High High
Targeted Disruption 60 93.40 High High
Body Weight 6 89.84 High High
Congenital Anomalies 11 88.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
No significant change in UPDRS scores, the primary endpoint, was observed, though serum CoQ10 levels were significantly elevated in all patients to a degree similar to levels attained with 1,200 mg in the phase II trial reported by Shults and colleagues.
Positive_regulation (elevated) of CoQ10
1) Confidence 0.58 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.57 Pain Relevance 0
Serum CoQ10 levels were decreased at baseline in FA patients, and were significantly increased in both groups (3.4-fold in the low-dose group, 12.2-fold in the high-dose group).
Positive_regulation (increased) of CoQ10 associated with ataxia
2) Confidence 0.58 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.51 Pain Relevance 0
Brooksbank and McGovern (1989) and Crino et al. (1989) also reported changes of ganglioside composition in AD brains in which b-series gangliosides, such as GT1b and GD1b, showed a significant decrease, in contrast with a slight increase in GT1a, GD3, GM1 and GM2.
Positive_regulation (increase) of GM1 in brains
3) Confidence 0.46 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2948441 Disease Relevance 0.17 Pain Relevance 0.09
The mean lifetime in vesicles was 20-30% lower than in the aqueous medium and showed a definite increase in presence of GM1 from that in the absence of it.
Positive_regulation (increase) of GM1 in vesicles
4) Confidence 0.43 Published 2004 Journal Chem. Phys. Lipids Section Abstract Doc Link 15172834 Disease Relevance 0 Pain Relevance 0.05
In healthy animals, oral administration of CoQ10 increases CoQ10 levels in the brain of older animals, whereas there is no effect on CoQ10 levels in young animals.
Positive_regulation (increases) of CoQ10 in brain
5) Confidence 0.42 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.96 Pain Relevance 0.07
Therefore we evaluated the effects of higher concentrations of GM1 and A?
Positive_regulation (concentrations) of GM1
6) Confidence 0.41 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.10 Pain Relevance 0
-III tubulin, a marker protein of mature neurons scarcely found in untreated NECs, was not increased in GM1- and A?
Neg (not) Positive_regulation (increased) of GM1 in neurons
7) Confidence 0.41 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2838405 Disease Relevance 0.32 Pain Relevance 0.04
Experiments on quenching of fluorescence from membrane-associated dibucaine by potassium iodide showed reduced quenching efficiency with the increase in GM1 content of the vesicles, demonstrating lesser accessibility of the iodide quenchers to dibucaine in the presence of GM1, when compared to that in its absence.
Positive_regulation (increase) of GM1 in vesicles
8) Confidence 0.40 Published 2004 Journal Chem. Phys. Lipids Section Abstract Doc Link 15172834 Disease Relevance 0 Pain Relevance 0.07
Exogenous CoQ10 has been shown to improve energy metabolism and activate energy production by cardiac myocytes.
Positive_regulation (activate) of CoQ10 in cardiac myocytes
9) Confidence 0.40 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.71 Pain Relevance 0
In the triple mutant mice, b-series gangliosides, including GD3, were completely absent, but GM1 and GD1a were significantly increased by 63.8% and 50.8% respectively.
Positive_regulation (increased) of GM1
10) Confidence 0.40 Published 2010 Journal ASN NEURO Section Body Doc Link PMC2948441 Disease Relevance 0.42 Pain Relevance 0
Matthews and colleagues demonstrated a 30%–40% increase in cerebral cortex mitochondrial concentrations of CoQ9 and CoQ10 at 12 months in mice,2 and Smith and colleagues found brain levels of CoQ9 and CoQ10 to increase with oral supplementation in R6/2 mouse models of HD.8 Central nervous system penetration of oral CoQ10 in humans has not been studied.


Positive_regulation (increase) of CoQ10 in cerebral cortex associated with central nervous system, disease and cerebral cortex
11) Confidence 0.39 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.73 Pain Relevance 0.12
In R6/2 and N171–82Q transgenic mouse models of HD, oral administration of coenzyme Q10 significantly prolonged survival and delayed motor deficits, weight loss, cerebral atrophy, and appearance of neuronal intranuclear inclusions.45 Brain levels of CoQ10 and CoQ9 were significantly lower in R6/2 mice relative to wild type mice, and oral supplementation with CoQ10 increased brain levels of CoQ9, CoQ10, and ATP, and reduced 8-hydroxy-2-deoxyguanosine levels.
Positive_regulation (increased) of CoQ10 in brain associated with targeted disruption, weight loss, frailty and disease
12) Confidence 0.39 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785862 Disease Relevance 0.69 Pain Relevance 0.07
These results show that simvastatin administration does not affect the serum CoQ10 increasing level by CoQ10 administration.
Neg (not) Positive_regulation (increasing) of CoQ10
13) Confidence 0.33 Published 2007 Journal Journal of Clinical Biochemistry and Nutrition Section Body Doc Link PMC2275764 Disease Relevance 0.28 Pain Relevance 0
Such GM1 elevation promotes coupling of opioid receptor with Gs, resulting in attenuation of inhibitory opioid effects and induction of a sustained excitatory response.
Positive_regulation (elevation) of GM1 associated with opioid receptor and opioid
14) Confidence 0.16 Published 1998 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 9668347 Disease Relevance 0.08 Pain Relevance 0.59
GM1 is significantly elevated in chronic opioid-treated cells via Gs/adenylyl cyclase activation.
Positive_regulation (activation) of GM1 associated with opioid
15) Confidence 0.14 Published 1998 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 9668347 Disease Relevance 0.08 Pain Relevance 0.57
GM1 is significantly elevated in chronic opioid-treated cells via Gs/adenylyl cyclase activation.
Positive_regulation (elevated) of GM1 associated with opioid
16) Confidence 0.14 Published 1998 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 9668347 Disease Relevance 0.07 Pain Relevance 0.55
Such elevation of GM1 would be expected to enhance the efficacy of excitatory opioid receptor activation of the Gs/adenylate cyclase/cyclic AMP system, thereby providing a positive feedback mechanism that may account for the remarkable supersensitivity of chronic opioid-treated neurons to the excitatory effects of opioid agonists as well as antagonists.
Positive_regulation (elevation) of GM1 in neurons associated with mu agonist, antagonist, opioid receptor and opioid
17) Confidence 0.11 Published 1995 Journal J. Neurosci. Res. Section Abstract Doc Link 8568936 Disease Relevance 0.35 Pain Relevance 1.42
Chronic opioid treatment of neuroblastoma x dorsal root ganglion neuron hybrid F11 cells results in elevated GM1 ganglioside and cyclic adenosine monophosphate levels and onset of naloxone-evoked decreases in membrane K+ currents.
Positive_regulation (elevated) of GM1 in F11 associated with ganglion cysts, dorsal root ganglion, neuroblastoma, adenocard, narcan and opioid
18) Confidence 0.11 Published 1995 Journal J. Neurosci. Res. Section Title Doc Link 8568936 Disease Relevance 0.44 Pain Relevance 0.94
We show that chronic opioid exposure of F11 cells does, in fact, result in elevated levels of GM1 as well as cyclic adenosine monophosphate (AMP), concomitant with the onset of opioid excitatory supersensitivity as manifested by naloxone-evoked decreases in voltage-dependent membrane K+ currents.
Positive_regulation (elevated) of GM1 in F11 associated with adenocard, narcan and opioid
19) Confidence 0.11 Published 1995 Journal J. Neurosci. Res. Section Abstract Doc Link 8568936 Disease Relevance 0.38 Pain Relevance 1.13
A decrease in gangliosides belonging to the b-series (GD3, GD1b, GT1b and GQ1b) in parallel with an increase in that of the a-series (GM2, GM1 and GD1a) were found for both the ethanol plus pentazocine and the high-carbohydrate fed rats.
Positive_regulation (increase) of GM1 associated with fortral
20) Confidence 0.10 Published 1994 Journal Arch. Toxicol. Section Abstract Doc Link 7998825 Disease Relevance 0 Pain Relevance 0.48

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox